Capivasertib Plus Fulvestrant Gains EU Approval for Advanced Breast Cancer

Thursday, 20 June 2024 | Women's Cancers

Capivasertib, in combination with fulvestrant, has received approval from the European Union (EU) for treating adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer. This approval targets patients with specific genetic alterations (PIK3CA, AKT1, or PTEN) who have experienced disease recurrence or progression following an endocrine-based regimen.

To continue, please login or sign up first